W e read with great interest the article by Burdess and colleagues published in the July 2010 issue of Annals of Surgery, which reported a randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. 1 They found that in patients with critical limb ischemia, combined perioperative aspirin and clopidogrel therapy reduced biomarkers of atherothrombosis without causing unacceptable bleeding. 1 Their findings are intriguing because perioperative cardiovascular complications are not uncommon in patients undergoing peripheral vascular surgery. We agree that large-scale randomized controlled trials are needed to establish whether dual antiplatelet therapy can improve clinical outcomes in high-risk patients undergoing vascular surgery, whereas we have some concerns about the study design and the interpretation of their results.
Multiple lines of evidence point to bleeding as the main side effects of clopidogrel alone or in combination with aspirin. 2, 3 Although in this study there was no increase in major life-threatening bleeding (14% vs. 10%; RR: 1.4, 95% CI: 0.49-3.76; P = 0.56), we believe that the insignificance regarding minor bleeding (34% vs. 21%; RR 1.64, 95% CI: 0.87-3.1; P = 0.12) might be due to the relatively small sample size, which is particularly supported by the increased rate of major nonlife-threatening (RR: 3.19, 95% CI: 1.08-9.4, P = 0.024) and blood transfusions (28% vs. 12.6%, RR: 2.3, 95% CI: 1.0-5.29; P = 0.037). 1 As mentioned by the authors, peripheral arterial disease affects nearly 30 million people in Western Europe and North America. In up to 3 quarters of the cases, patients with peripheral arterial disease have coexistent coronary artery disease and a 3-fold increased risk of cardiovascular events and death. 4 Because the occurrence of perioperative cardiac complications in vascular surgeries is associated with long-term cardiac death, clearly the need to reduce cardiovascular events in patients with peripheral arterial Disclosure: The authors declare no conflicts of interest or funding sources. Copyright C 2011 by Lippincott Williams & Wilkins ISSN: 0003-4932/11/25902-e0031 DOI: 10.1097/SLA.0b013e318226a5ef disease remains unmet during the perioperative period. Therefore, it is reasonable that we hypothesize that clopidogrel in combination with aspirin is more effective in lowering the risk of cardiovascular events and death in patients undergoing surgery for critical limb ischemia. However, this study failed to show such a potential for dual antiplatelet therapy. It has been well established that clopidogrel and aspirin can lower the risk of cardiovascular events efficiently. 5 Also, as shown and acknowledged by the authors, bleeding and blood transfusions were increased in their study. In terms of these premises, it would be safer to screen out the aforementioned 3 quarters of patients who are at higher risk for cardiovascular events and death before surgery and the administration of dual antiplatelet therapy. Because half of the troponin-positive events occurred before surgery, these patients might be more vulnerable to surgical stress that results in cardiovascular events and deaths as compared with the other half with troponin-positive events occurring after surgery, although further studies are still needed to confirm it. In this regard, we agree with the authors to initiate therapy before surgery, given the relatively high incidence of troponin-positive events before surgery.
We are also eager to know if the authors assessed the correlation between the curative effects of the surgery for critical limb ischemia and the use of dual antiplatelet therapy. Although limited by the sample size, the prognostic analysis seems of great value to support or argue against perioperative dual antiplatelet therapy.
Another concern that arises from this study is the anesthetic method the authors utilized. Theoretically, general anesthesia may lead to more severe abnormality in homeostasis of coagulation and anticoagulation. In patients with high-risk coronary artery disease, local anesthesia was found to have theoretical and practical advantages and was suggested to be an alternative to general and regional anesthesia. 6 In addition, studies have revealed that epidural anesthesia has advantages over general anesthesia in patients with occlusive atherosclerotic disease who undergo vascular surgery in the lower limbs, because epidural anesthesia allows maintenance of good hemodynamic stability and elicits less stress reactions. 7 In the light of these findings, myocardial injuries as marked by serum levels of troponin in this study might to some extent, be averted by more alternative use of epidural anesthesia or local anesthesia.
In summary, dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia appears promising, especially for patients with high-risk of cardiovascular events, though further studies are needed to evaluate the benefit/risk ratio, as well as to explore the optimal strategy of dual antiplatelet therapy.
